Firefly Highlights Versus Platform in Non-Invasive Brain-Computer Interface Strategy

Key Points

• Firefly’s commercially available Versus platform combines a wireless EEG headset with interactive training software.
• The company reports more than 3,000 headsets shipped and says the platform generates commercial revenue.
• Users influence flight and driving simulations through real-time brainwave activity, receiving feedback while practicing focus and brain-state regulation.
• Firefly is also developing an EEG/ERP-based AI foundation model using a database of more than 200,000 standardized brain scans.
• The announcement is a strategy update, not a new clinical validation, regulatory clearance or quantified financial milestone.

Firefly Neuroscience (NASDAQ: AIFF) is positioning Versus as its current commercial entry into non-invasive brain-computer interfaces, while pursuing longer-term opportunities through AI and brain-signal analysis.

The company’s strategy connects an available training product with a foundation model still under development. The announcement does not establish that the model’s proposed capabilities are already available in Versus.

Versus Turns Brainwave Activity Into Interactive Feedback

Versus uses dry-sensor EEG to measure brainwave activity and transmit signals wirelessly to interactive software. Flight and driving simulations respond to targeted brain-activity patterns, providing immediate feedback as users practice maintaining focus and regulating their brain state.

Session-level tracking lets users monitor progress over time. Firefly sees the combination of portable hardware and interactive software as a starting point for additional human-performance applications.

The announcement describes brainwave-responsive training—not unrestricted thought control or demonstrated improvements in everyday cognitive performance.

Shipments Establish Commercial Activity, but Financial Detail Is Limited

Firefly reports that more than 3,000 Versus headsets have shipped and that the platform generates revenue.

However, the announcement does not disclose the shipment period, active-user count, platform revenue, recurring software revenue or profitability. The shipment figure therefore establishes product distribution, but does not by itself show the pace of growth or ongoing customer engagement.

Foundation Model Remains a Longer-Term Development Opportunity

Firefly’s separate foundation model initiative draws on its database of more than 200,000 standardized EEG/ERP scans, its Evoke platform, AI capabilities and NVIDIA GPU acceleration.

Management believes that work could eventually support more personalized training, improved interpretation of brain signals, biomarker discoveries and new BCI applications. The company explicitly makes those opportunities subject to further development and validation.

The announcement identifies Evoke as FDA 510(k)-cleared. It does not state that Versus or the proposed foundation model has that same clearance.

References to Other BCI Companies Do Not Establish Partnerships

Management mentions Neuralink and Merge Labs as examples of companies advancing the broader BCI field. The announcement does not disclose a partnership, commercial agreement or technical integration with either company.

Similarly, Firefly’s description of its planned model as potentially the world’s first EEG/ERP-based brain foundation model is a company claim, not an independently established finding in the supplied source.

Investor Takeaway: A Commercial Product Alongside an Unproven AI Opportunity

For AIFF investors, the update highlights two distinct parts of the business: a revenue-generating Versus platform today and a foundation model that could support future products.

The main unanswered questions are commercial scale and technical validation. The release provides no new revenue figures, model-performance results, development completion date or evidence that the proposed AI capabilities have improved customer outcomes.